OrbiMed Advisors co-led an oversubscribed series A financing of a new company creating RNA therapies for rare pulmonary diseases including cystic fibrosis.
ReCode Therapeutics announced an . . .
Continue Reading With a Free Trial
Unlock this article instantly, along with the rest of our premium content, newsletters and mandate charts.
Already a subscriber? Log in.